An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

Summary

This is an exploratory study with the following primary objectives: 1) to establish that PET/CT of the lung can reliably distinguish healthy, non-asthmatic participants from participants with severe asthma and an eosinophilic phenotype and 2) to examine the utility of PET/CT for demonstrating that reslizumab produces a reduction in lung inflammation in participants with severe asthma and an eosinophilic phenotype .

Timeline

Start

2017-05-08

Primary completion

2017-05-24

Completion

2017-05-24

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated early due to challenges in recruitment. The decision to terminate the study was not related to any safety issues or concerns.”

Drugs

Indications